TG-C

Phase 3Biologic

KKolon TissueGene, Inc.

TG-C is one of 60 biologic programs targeting Back pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Back PainActive, not recruiting

OsteoarthritisCompleted

Back PainPhase 1

Active, not recruiting

OsteoarthritisPhase 3

Completed

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

TG-C

KKolon TissueGene, Inc.

Phase 3

2 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Ilaris

Novartis

Preclinical

2 4

Cataflam

Chirocaine

1 6

Lunesta

Akero Therapeutics

Preclinical

1 7

Naproxen Sodium

Bayer

Preclinical

1 8

Ansaid

PPharmacia and Upjohn

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Ozone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Osteoarthritis

NCT05276011

Q4 2027

Phase 1Not yet recruiting

Back Pain

NCT06144970

Clinical

Trials by Indication[1]

Osteoarthritis2 trials

A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis

Not yet recruiting·KKolon TissueGene, Inc.·Phase 2·NCT05276011·255 enrolled

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee

Completed·KKolon TissueGene, Inc.·Phase 3·NCT03291470·531 enrolled

Back pain1 trial

Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease

Not yet recruiting·KKolon TissueGene, Inc.·Phase 1·NCT06144970·24 enrolled

Safety and Efficacy1 trial

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

Active, not recruiting·KKolon TissueGene, Inc.·Phase 3·NCT03203330·535 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TG-C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TG-C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TG-C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kolon TissueGene, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: KKolon TissueGene, Inc.

TG-C

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Osteoarthritis2 trials

Back pain1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News